149 related articles for article (PubMed ID: 10732772)
21. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
[TBL] [Abstract][Full Text] [Related]
22. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
23. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis.
Hrabec E; Strek M; Nowak D; Greger J; Suwalski M; Hrabec Z
J Cancer Res Clin Oncol; 2002 Apr; 128(4):197-204. PubMed ID: 11935310
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.
Waas ET; Wobbes T; Lomme RM; DeGroot J; Ruers T; Hendriks T
Br J Surg; 2003 Dec; 90(12):1556-64. PubMed ID: 14648736
[TBL] [Abstract][Full Text] [Related]
25. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
26. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer.
Bogusiewicz M; Stryjecka-Zimmer M; Szymanski M; Rechberger T; Golabek W
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):132-6. PubMed ID: 12574771
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
28. Experimental hindlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and -9 activity: a potential mechanism for ischemia induced MMP activation.
Muhs BE; Gagne P; Plitas G; Shaw JP; Shamamian P
J Surg Res; 2004 Apr; 117(2):249-54. PubMed ID: 15047130
[TBL] [Abstract][Full Text] [Related]
29. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-2 and -9 involvement in canine tumors.
Loukopoulos P; Mungall BA; Straw RC; Thornton JR; Robinson WF
Vet Pathol; 2003 Jul; 40(4):382-94. PubMed ID: 12824510
[TBL] [Abstract][Full Text] [Related]
31. Introduction of preoperative radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands.
Vermaas M; Gosselink MP; Ferenschild FT; van den Aardweg E; Lont HE; Kemperman HW; van der Harst E; Tetteroo GW; Oostenbroek RJ; Dijkhuis CM; Eggermont AM; de Wilt JH
Eur J Surg Oncol; 2007 Sep; 33(7):862-7. PubMed ID: 17257804
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinases in mild and severe temporomandibular joint internal derangement synovial fluid.
Srinivas R; Sorsa T; Tjäderhane L; Niemi E; Raustia A; Pernu H; Teronen O; Salo T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 May; 91(5):517-25. PubMed ID: 11346728
[TBL] [Abstract][Full Text] [Related]
33. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT
J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946
[TBL] [Abstract][Full Text] [Related]
34. Effect of preoperative radiotherapy on matrilysin gene expression in rectal cancer.
Kumar A; Collins H; Van Tam J; Scholefield JH; Watson SA
Eur J Cancer; 2002 Mar; 38(4):505-10. PubMed ID: 11872342
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
Vestermark LW; Jacobsen A; Qvortrup C; Hansen F; Bisgaard C; Baatrup G; Rasmussen P; Pfeiffer P
Acta Oncol; 2008; 47(3):428-33. PubMed ID: 18348002
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer.
Okada N; Ishida H; Murata N; Hashimoto D; Seyama Y; Kubota S
Biochem Biophys Res Commun; 2001 Oct; 288(1):212-6. PubMed ID: 11594775
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation.
Angenete E; Langenskiöld M; Falk P; Ivarsson ML
Int J Colorectal Dis; 2007 Jun; 22(6):667-74. PubMed ID: 17109104
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant radiochemotherapy increases matrix metalloproteinase activity in healthy tissue in esophageal cancer patients.
Rieff EA; Hendriks T; Rutten HJ; Nieuwenhuijzen GA; Gosens MJ; van den Brule AJ; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2009 May; 16(5):1384-9. PubMed ID: 19224281
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
